- Home
- LDWY vs KPRX Comparison
LDWY vs KPRX Comparison
Compare LDWY & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LDWY
- KPRX
- Stock Information
- Founded
- LDWY 1990
- KPRX 1998
- Country
- LDWY United States
- KPRX United States
- Employees
- LDWY N/A
- KPRX N/A
- Industry
- LDWY Advertising
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- LDWY Consumer Discretionary
- KPRX Health Care
- Exchange
- LDWY Nasdaq
- KPRX Nasdaq
- Market Cap
- LDWY 9.2M
- KPRX 7.9M
- IPO Year
- LDWY 1991
- KPRX N/A
- Fundamental
- Price
- LDWY $4.95
- KPRX $2.46
- Analyst Decision
- LDWY
- KPRX Strong Buy
- Analyst Count
- LDWY 0
- KPRX 1
- Target Price
- LDWY N/A
- KPRX $10.00
- AVG Volume (30 Days)
- LDWY 4.6K
- KPRX 62.2K
- Earning Date
- LDWY 08-18-2025
- KPRX 08-08-2025
- Dividend Yield
- LDWY N/A
- KPRX N/A
- EPS Growth
- LDWY N/A
- KPRX N/A
- EPS
- LDWY N/A
- KPRX N/A
- Revenue
- LDWY $42,183,000.00
- KPRX N/A
- Revenue This Year
- LDWY N/A
- KPRX N/A
- Revenue Next Year
- LDWY N/A
- KPRX N/A
- P/E Ratio
- LDWY N/A
- KPRX N/A
- Revenue Growth
- LDWY 425.12
- KPRX N/A
- 52 Week Low
- LDWY $3.02
- KPRX $2.25
- 52 Week High
- LDWY $5.60
- KPRX $4.29
- Technical
- Relative Strength Index (RSI)
- LDWY 49.85
- KPRX 38.09
- Support Level
- LDWY $4.95
- KPRX $2.27
- Resistance Level
- LDWY $5.06
- KPRX $3.29
- Average True Range (ATR)
- LDWY 0.16
- KPRX 0.15
- MACD
- LDWY -0.01
- KPRX -0.03
- Stochastic Oscillator
- LDWY 59.11
- KPRX 31.82
About LDWY Lendway Inc. (DE)
Lendway Inc is a specialty agricultural and finance company focused on making and managing its ag investments in the United States and internationally. The company operates in two industries: Specialty Ag, consisting of the Bloomia business, and Non-bank Lending, consisting of the Lending Business.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.